The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations. 3 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
The Danish government is to remove the rules that currently prohibit the purchase of medicines from countries outside the European Union (EU) in a move that has not been welcomed by pharma. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). 30 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
President Biden has said the USA will commit at least $500 million to support African countries in battling the ongoing mpox outbreak in Central and Eastern Africa. 25 September 2024
The Pharmaceutical Research and Manufacturers of America (PhRMA) is continuing its legal challenge against the US government’s drug pricing reforms. 24 September 2024
The Foundation for Economic and Industrial Research and Greek pharma trade group the Hellenic Association of Pharmaceutical Companies have presented two studies reflecting the industry’s importance. 23 September 2024
Basilea Pharmaceutica announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) has awarded Basilea an Other Transaction Agreement (OTA), under OTA number 75A50124C00033. 20 September 2024
Novo Nordisk is under increasing pressure over the cost of its blockbuster drugs in the USA, as chief executive Lars Fruergaard Jørgensen prepares to testify before a powerful Senate committee. 18 September 2024
The research based pharmaceutical industry has welcomed Mario Draghi’s report, published by the European Commission, outlining proposals on how Europe can regain its competitive edge and the critical role of innovative industries in achieving this. 11 September 2024
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
The US House of Representatives has passed the BIOSECURE Act, gaining bipartisan support with a vote of 306–81. Nearly all of the votes against the bill came from Democrats. 10 September 2024
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
The budget on October 30 is an opportunity to end short-termism, cut waste, and attract long-term investment to the country’s economy with a sector-targeted R&D tax relief policy, according to the UK BioIndustry Association (BIA). 3 September 2024
The Danish Pharmaceutical Industry Association, Lif, has given its verdict on the government financial bill setting out new priorities in health in 2025. 2 September 2024
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024
Two weeks after Americans voted in the presidential election, the losing candidate, Donald Trump, remains in denial over the outcome of the poll. 18 November 2020
The Russian government may consider increasing state funding for public procurements of drugs in the next several years, according to recent statements, made by an official spokesman of the federal government and some local media reports. 17 November 2020
The high and rising cost of prescription drugs in the United States remains a concern for patients, physicians, payers, and policy makers. It is also a key priority for the US Food and Drug Administration, the Trump administration, and the Department of Health and Human Services (HHS). 16 November 2020
Brazil’s pharmaceutical industry is the largest in Latin America and currently the seventh biggest in the world though, according to projections from IQVIA, it could be in fifth position in 2023. 16 November 2020
Private equity (PE) investors are betting big on Indian drug makers, especially those that manufacture active pharmaceutical ingredients (APIs), with investments jumping more than fourfold so far this year. 11 November 2020
In timely fashion, a deal has been announced for the European Commission (EC) to be supplied with 200 million doses of the Pfizer and BioNTech mRNA-based vaccine candidate against COVID-19. 11 November 2020
The US Department of Health and Human Services on Tuesday announced plans to allocate initial doses of Eli Lilly's investigational monoclonal antibody therapeutic, bamlanivimab, which received emergency use authorization from the US Food and Drug Administration November 9 for the treatment of non-hospitalized patients with mild or moderate confirmed cases of COVID-19. 11 November 2020
Pharmasynthez, one of Russia’s leading drugmakers, has asked for permission to begin production of a generic of remdesivir, an original drug from US antivirals giant Gilead Sciences, reports The Pharma Letter’s local correspondent. 10 November 2020
Russian patients have called on the national government to take measures to prevent the ever-growing shortage of drugs in the domestic market, particular those that could be recommended for the treatment of COVID-19. 10 November 2020
No fewer than six bodies representing the pharmaceutical industry in the UK and Europe have expressed relief at the agreement for a phased process for implementing medicines regulation in Northern Ireland up to December 31, 2021. 9 November 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, trade body Pharmaceutical Research and Manufacturers of America (PhRMA) has outlined a number of commonsense ways policymakers can get the 340B program back on track and refocused on patients. 3 November 2020
Indian drug companies have a new ally. The UAE government is all set to provide incentives, including financial contributions, and will help create a full ecosystem to support Indian pharmaceutical companies having strong research and development facilities, reports The Pharma Letter’s India correspondent. 2 November 2020
Even as the Madras High court raises concern over India’s over-dependence on Chinese pharma ingredients, the Indian government has expanded and amended the Production-Linked Incentive (PLI) scheme aimed at strengthening India's indigenous production of active pharmaceutical ingredients (APIs). 30 October 2020
For two years from January 1, 2021, once the transition period after Brexit has come to an end, the UK will adopt decisions taken by the European Commission (EC) on the approval of new medicines in the community marketing authorization procedure. 27 October 2020
In Russia, 10 industry associations of the pharmaceutical market have turn to the Head of Government, as the situation with medicine labelling is becoming extremely critical for the supply of drugs, notes a posting on the website of the Association of International Pharmaceutical Manufacturers (AIPM). 26 October 2020
PharmaLex, a provider of specialized services for the pharma, biotech and health industries, has drafted a whitepaper focusing on the challenges Brexit poses to the pharmaceutical industry and what actions are required now to ensure companies remain compliant once the transition phase ends. (https://www.pharmalex.com/. An outline of this follows. 23 October 2020
Reducing patient healthcare costs is imperative, write Matthew Majewski and Andrew Parece, vice presidents of Charles River Associates, in a Special Report. 21 October 2020
The pharmaceutical industry and others involved in the supply of medical items in the UK want the Prime Minister to get a trade deal with the European Union. 16 October 2020